
Seattle-based Phase Genomics, Inc., founded in 2015, specializes in commercial bio-physical research and development.
Phase Genomics, Inc., founded in 2015 and based in Seattle, specializes in commercial bio-physical research and development. The company offers ultra-long-range genome sequencing technology and computational tools designed to empower scientists in addressing pressing health and environmental challenges. Their products and services focus on cytogenetics, oncology, and metagenomics, enabling the identification and characterization of chromosomal abnormalities to better understand the genetic basis of cancer and inherited diseases.
Phase Genomics has made significant strides in transforming genomic discovery through its innovative technologies. By providing high-resolution assays, the company has contributed to advancements in understanding complex genetic conditions. Their impact is evident in the scientific community's ability to tackle critical health issues more effectively. Notable achievements include collaborations with leading research institutions and contributions to groundbreaking studies in genomics.

Genome Insight

Sequegenics
sequegenics.com

Gencove
gencove.com

Singular Genomics

Ultima Genomics
ultimagenomics.com

Full Genomes
fullgenomes.com

Bionano Genomics
bionano.com

Genomenon
genomenon.com

ProPhase Labs
prophaselabs.com

Genometry

Base5 Genomics
b5genomics.com

Paragon Genomics

Streamline Genomics

Lightspeed Genomics

GenomeNext
Companies similar to Phase Genomics include Genome Insight, Sequegenics, Gencove and Singular Genomics.
Phase Genomics was founded in 2015.
Phase Genomics' headquarters is located in Seattle, WA, US.
Phase Genomics' most recent funding round was for $5.5M (USD) in June 2022.
As of Jun 9, 2022, Phase Genomics has raised a total of $15.3M (USD).
Phase Genomics has 30 employees as of Feb 5, 2024.